The first human trial to evaluate a candidate vaccine against coronavirus disease 2019 has begun in Seattle, US health officials said on Monday. “The open-label trial will enroll 45 healthy adult volunteers, aged 18 to 55 years over approximately six weeks,” the US National Institutes of Health said in a statement. “The first participant received the investigational vaccine today.” (AFP) 